Interstitial granulomatous drug reaction to sorafenib

Archives of Dermatology

Volumn 147, Issue 9, 2011, Pages 1118-1119

  Martínez Morán, Cristina ^a   Nájera, Laura ^a   Ruiz Casado, Ana I ^a   Romero Maté, Alberto ^a   Espinosa, Pablo ^a   Meseguer Yebra, Carmen ^a   Córdoba, Susana ^a   Borbujo, Jesús M ^a  

^a HOSPITAL UNIVERSITARIO DE FUENLABRADA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CLOBETASOL; SORAFENIB;

AGED; CASE REPORT; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; GLOSSITIS; GRANULOMATOUS SKIN DISEASE; HAND FOOT SYNDROME; HEPATITIS C; HISTOPATHOLOGY; HUMAN; LETTER; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; MEDICAL HISTORY; PHYSICAL EXAMINATION; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PUNCH BIOPSY; THROMBOCYTOPENIA;

AGED; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; DRUG ERUPTIONS; FOOT DERMATOSES; GRANULOMA; HAND DERMATOSES; HUMANS; MALE; PROTEIN KINASE INHIBITORS; PYRIDINES;

EID: 80053085454     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2011.241     Document Type: Letter

References (6)

1. Magro CM, Crowson AN, Schapiro BL. The interstitial granulomatous drug reaction: a distinctive clinical and pathological entity. J Cutan Pathol. 1998;25(2):72-78. (Pubitemid 28073644)
2. Martorell-Calatayud A, Balmer N, Cardenas Cardona LF, Teague D. Interstitial granulomatous drug reaction to adalimumab. Am J Dermatopathol. 2010;32(4):408-409.
3. Chen YC, Hsiao CH, Tsai TF. Interstitial granulomatous drug reaction presenting as erythroderma: remission after discontinuation of enalapril maleate. Br J Dermatol. 2008;158(5):1143-1145. (Pubitemid 351521437)
4. Marcollo Pini A, Kerl K, Kamarachev J, French LE, Hofbauer GF. Interstitial granulomatous drug reaction following intravenous ganciclovir. Br J Dermatol. 2008;158(6):1391-1393. (Pubitemid 351692887)
5. Lee WJ, Lee JL, Chang SE, et al. Cutaneous adverse effects in patients treated with themultitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol. 2009;161(5):1045-1051.
6. Robert C, Mateus C, Spatz A, Wechsler J, Escudier B. Dermatologic symptoms associated with the multikinase inhibitor sorafenib. J Am Acad Dermatol. 2009;60(2):299-305.